{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:49:40Z","timestamp":1780073380161,"version":"3.54.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WOODS19A0"],"award-info":[{"award-number":["WOODS19A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001425"],"award-info":[{"award-number":["UL1TR001425"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"crossref","award":["WOODS19A0"],"award-info":[{"award-number":["WOODS19A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001425"],"award-info":[{"award-number":["UL1TR001425"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Elexacaftor\/tezacaftor\/ivacaftor (ETI) has significantly improved lung function in people with cystic fibrosis (CF), prompting the need for outcome measures that can detect mild disease. In this new era of CFTR (CF transmembrane regulator) modulator therapy, more sensitive endpoints are required to evaluate the progression of early lung disease and to determine the efficacy of new CF therapies. Before the availability of highly effective therapies, xenon-129 magnetic resonance imaging (MRI) was shown to be more sensitive to regional ventilation changes compared with spirometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the longitudinal changes in pulmonary function and Xe MRI outcomes after treatment with ETI in children and young people with CF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Lung function was assessed longitudinally at baseline and 1, 6, and 12 months after ETI treatment initiation in children and young people with CF between the ages of 6 and 18 years at four study sites. Ventilation defect percentage (VDP), reader defect percentage (RDP), lung clearance index (LCI) and forced expiratory volume in 1 second (FEV1) were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 28 participants were enrolled; 25 completed at least baseline and one-month measurements. All four measures (RDP, VDP, LCI, and FEV1) improved at one month after ETI initiation, with mean (standard deviation) absolute changes of \u22121.2 (1.7) in LCI, 6.9 (12.3) in FEV1 % predicted, \u22124.3 (4.8) in VDP, and \u22127.8 (9.6) in RDP. Xe MRI outcomes (RDP and VDP) showed the largest relative treatment effects, with mean relative improvements of 43% and 72%, respectively. One-third of participants (8 of 25) had improvements in VDP and RDP but did not show improvements in FEV1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Xe MRI captures sustained ventilation improvements after ETI initiation. Xe MRI metrics may provide a suitable endpoint for future interventional trials, particularly for people with CF with mild lung disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202501-028oc","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T20:00:21Z","timestamp":1755028821000},"page":"1891-1899","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":5,"title":["Multicenter Study of Hyperpolarized Xenon Magnetic Resonance Imaging in Children with Cystic Fibrosis Following Initiation of Cystic Fibrosis Transmembrane Regulator Modulator Therapy (HyPOINT)"],"prefix":"10.1093","volume":"22","author":[{"given":"Felix A.","family":"Ratjen","sequence":"first","affiliation":[{"name":"Translational Medicine Program, Division of Respiratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Stanojevic","sequence":"additional","affiliation":[{"name":"Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samal","family":"Munidasa","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Imaging Research, Division of Pulmonary Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roach","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Imaging Research, Division of Pulmonary Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Mata","sequence":"additional","affiliation":[{"name":"Department of Radiology"},{"name":"Department of Medical Imaging, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Froh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Zanette","sequence":"additional","affiliation":[{"name":"Translational Medicine Program, Division of Respiratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Santyr","sequence":"additional","affiliation":[{"name":"Translational Medicine Program, Division of Respiratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean B.","family":"Fain","sequence":"additional","affiliation":[{"name":"Department of Medical Physics and"},{"name":"Department of Radiology, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rock","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-6401","authenticated-orcid":false,"given":"Laura L.","family":"Walkup","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Imaging Research, Division of Pulmonary Medicine"},{"name":"Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Woods","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Imaging Research, Division of Pulmonary Medicine"},{"name":"Department of Radiology, and"},{"name":"Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026020221030590600_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"2026020221030590600_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026020221030590600_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020221030590600_bib4","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00247-016-3672-1","article-title":"Feasibility, tolerability, and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and subjects with cystic fibrosis","volume":"46","author":"Walkup","year":"2016","journal-title":"Pediatr Radiol"},{"key":"2026020221030590600_bib5","doi-asserted-by":"crossref","first-page":"20210207","DOI":"10.1259\/bjr.20210207","article-title":"Lung MRI with hyperpolarised gases: current & future clinical perspectives","volume":"95","author":"Stewart","year":"2022","journal-title":"Br J Radiol"},{"key":"2026020221030590600_bib6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.acra.2018.04.024","article-title":"Hyperpolarized gas magnetic resonance imaging of pediatric cystic fibrosis lung disease","volume":"26","author":"Santyr","year":"2019","journal-title":"Acad Radiol"},{"key":"2026020221030590600_bib7","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jcf.2023.01.017","article-title":"Short-term structural and functional changes after airway clearance therapy in cystic fibrosis","volume":"22","author":"West","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026020221030590600_bib8","doi-asserted-by":"crossref","first-page":"1802188","DOI":"10.1183\/13993003.02188-2018","article-title":"Hyperpolarised 129Xe MRI to monitor treatment response in children with cystic fibrosis","volume":"53","author":"Rayment","year":"2019","journal-title":"Eur Respir J"},{"key":"2026020221030590600_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcf.2016.07.008","article-title":"Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients","volume":"16","author":"Thomen","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026020221030590600_bib10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1164\/rccm.201611-2228LE","article-title":"Correlation of lung clearance index with hyperpolarized 129Xe magnetic resonance imaging in pediatric subjects with cystic fibrosis","volume":"196","author":"Kanhere","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020221030590600_bib11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/jmri.29605","article-title":"Same-day repeatability and 28-day reproducibility of xenon MRI ventilation in children with cystic fibrosis in a multi-site trial","volume":"61","author":"Walkup","year":"2024","journal-title":"J Magn Reson Imaging"},{"key":"2026020221030590600_bib12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jcf.2019.03.005","article-title":"A two-centre analysis of hyperpolarized 129Xe lung MRI in stable pediatric cystic fibrosis: potential as a biomarker for multi-site trials","volume":"18","author":"Couch","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026020221030590600_bib13","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/mrm.28985","article-title":"Protocols for multi-site trials using hyperpolarized 129Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: a position paper from the 129Xe MRI Clinical Trials Consortium","volume":"86","author":"Niedbalski","year":"2021","journal-title":"Magn Reson Med"},{"key":"2026020221030590600_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1183\/09031936.95.08030492","article-title":"Reference values for residual volume, functional residual capacity and total lung capacity: ATS workshop on lung volume measurements. Official statement of the European Respiratory Society","volume":"8","author":"Stocks","year":"1995","journal-title":"Eur Respir J"},{"key":"2026020221030590600_bib15","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.acra.2021.06.017","article-title":"Hyperpolarized 129xenon MRI ventilation defect quantification via thresholding and linear binning in multiple pulmonary diseases","volume":"29","author":"Roach","year":"2022","journal-title":"Acad Radiol"},{"key":"2026020221030590600_bib16","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2026020221030590600_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur Respir J"},{"key":"2026020221030590600_bib18","doi-asserted-by":"crossref","first-page":"e0157523","DOI":"10.1371\/journal.pone.0157523","article-title":"A systematic approach to multiple breath nitrogen washout test quality","volume":"11","author":"Jensen","year":"2016","journal-title":"PLoS One"},{"key":"2026020221030590600_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"2026020221030590600_bib20","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"2026020221030590600_bib21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/thoraxjnl-2021-218347","article-title":"Evaluation of clinically relevant changes in the lung clearance index in children with cystic fibrosis and healthy controls","volume":"78","author":"Perrem","year":"2023","journal-title":"Thorax"},{"key":"2026020221030590600_bib22","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.3390\/jcm11206160","article-title":"Dynamic perfluorinated gas MRI shows improved lung ventilation in people with cystic fibrosis after elexacaftor\/tezacaftor\/ivacaftor: an observational study","volume":"11","author":"Goralski","year":"2022","journal-title":"J Clin Med"},{"key":"2026020221030590600_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis\u2014a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026020221030590600_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00330-023-09912-6","article-title":"Effect of CFTR modulator therapy with elexacaftor\/tezacaftor\/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients","volume":"34","author":"Klime\u0161","year":"2024","journal-title":"Eur Radiol"},{"key":"2026020221030590600_bib25","doi-asserted-by":"crossref","first-page":"e230104","DOI":"10.1148\/ryct.230104","article-title":"PREFUL MRI for monitoring perfusion and ventilation changes after elexacaftor-tezacaftor-ivacaftor therapy for cystic fibrosis: a feasibility study","volume":"6","author":"Dohna","year":"2024","journal-title":"Radiol Cardiothorac Imaging"},{"key":"2026020221030590600_bib26","doi-asserted-by":"crossref","first-page":"2400004","DOI":"10.1183\/13993003.00004-2024","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles","volume":"64","author":"Stahl","year":"2024","journal-title":"Eur Respir J"},{"key":"2026020221030590600_bib27","doi-asserted-by":"crossref","first-page":"107328","DOI":"10.1016\/j.rmed.2023.107328","article-title":"Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor\/tezacaftor\/ivacaftor in adolescent and adult patients with cystic fibrosis","volume":"216","author":"Fainardi","year":"2023","journal-title":"Respir Med"},{"key":"2026020221030590600_bib28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.202006-2433OC","article-title":"Lung clearance index to track acute respiratory events in school-age children with cystic fibrosis","volume":"203","author":"Perrem","year":"2021","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/12\/1891\/66620960\/annalsats_22_12_1891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/12\/1891\/66620960\/annalsats_22_12_1891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T02:03:26Z","timestamp":1770084206000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/12\/1891\/8444139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202501-028oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"2025-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}